BRAF activation initiates but does not maintain invasive prostate adenocarcinoma

Cited 0 time in webofscience Cited 0 time in scopus
Jeong, Joseph H.; Wang, Zhenxiong; Guimaraes, Alexander S.; Ouyang, Xuesong; Figueiredo, Jose L.; Ding, Zhihu; Jiang, Shan; Guney, Isil; Kang, Gyeong Hoon; Shin, Eyoung; Hahn, William C.; Loda, Massimo F.; Abate-Shen, Cory; Weissleder, Ralph; Chin, Lynda
Issue Date
Public Library of Science
PLoS ONE 3(12): e3949
Prostate cancer is the second leading cause of cancer-related deaths in men. Activation of MAP kinase signaling pathway has been implicated in advanced and androgen-independent prostate cancers, although formal genetic proof has been lacking. In the course of modeling malignant melanoma in a tyrosinase promoter transgenic system, we developed a genetically-engineered mouse (GEM) model of invasive prostate cancers, whereby an activating mutation of BRAF(V600E)--a mutation found in approximately 10% of human prostate tumors--was targeted to the epithelial compartment of the prostate gland on the background of Ink4a/Arf deficiency. These GEM mice developed prostate gland hyperplasia with progression to rapidly growing invasive adenocarcinoma without evidence of AKT activation, providing genetic proof that activation of MAP kinase signaling is sufficient to drive prostate tumorigenesis. Importantly, genetic extinction of BRAF(V600E) in established prostate tumors did not lead to tumor regression, indicating that while sufficient to initiate development of invasive prostate adenocarcinoma, BRAF(V600E) is not required for its maintenance.
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Pathology (병리학전공)Journal Papers (저널논문_병리학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.